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Abstract
Introduction: Breast cancer is the most diagnosed and second leading cause of cancer deaths in the U.S. female
population. An estimated 5 to 10 percent of all breast cancers are inherited, caused by mutations in the breast
cancer susceptibility genes (BRCA1/2). As many as 90% of all mutations are nonsense mutations, causing a
truncated polypeptide product. A popular and low cost method of mutation detection has been the protein
truncation test (PTT), where target regions of BRCA1/2 are PCR amplified, transcribed/translated in a cell-free protein
synthesis system and analyzed for truncated polypeptides by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and autoradiography. We previously reported a novel High Throughput Solid-Phase PTT
(HTS-PTT) based on an enzyme-linked immunosorbent assay (ELISA) format that eliminates the need for
radioactivity, SDS-PAGE and subjective interpretation of the results. Here, we report the next generation HTS-PTT
using triple-epitope-tagged proteins and demonstrate, for the first time, its efficacy on clinical genomic DNA
samples for BRCA1/2 analysis.
Methods: Segments of exons 11 of BRCA1/2 open reading frames were PCR amplified from either blood derived
genomic DNA or cell line mRNA. PCR primers incorporate elements for cell-free transcription/translation and
epitope tagging. Cell-free expressed nascent proteins are then antibody-captured onto the wells of a microtiter
plate and the relative amount of truncated polypeptide measured using antibodies against the N- and C-terminal
epitope tags in an ELISA format.
Results: 100% diagnostic sensitivity and 96% specificity for truncating mutations in exons 11 of BRCA1/2 were
achieved on one hundred blood-derived clinical genomic DNA samples which were previously assayed using the
conventional gel based PTT. Feasibility of full gene coverage for BRCA1/2 using mRNA source material is also
demonstrated.
Conclusions: Overall, the HTS-PTT provides a simple, quantitative, objective, low cost and high throughput
method for analysis of truncating mutations as an alternative to gel based PTT for BRCA analysis. The technology is
readily accessible to virtually any laboratory, with the only major instrumentation required being a PCR
thermocycler and a basic micro-well plate reader. When compared to conventional gel based PTT, the HTS-PTT
provides excellent concordance.
Introduction
Breast cancer is the most diagnosed and second leading
cause of cancer deaths in the US female population, with
approximately 200,000 new cases and approximately
40,000 deaths reported annually [1]. Ovarian cancer is
the second ranking gynecological cancer, with approxi-
mately 22,000 cases and approximately 15,000 deaths
annually [1]. Approximately 3% to 5% of all breast
cancers and approximately 10% of ovarian cancers are
due to inherited mutations in the breast and ovarian can-
cer susceptibility 1 or 2 genes (BRCA1 or BRCA2) [2-4].
Lifetime risks of BRCA1/2 mutation carriers have been
estimated at approximately 80% for breast cancer and
approximately 40% and approximately 20% for ovarian
cancer (BRCA1 and BRCA2, respectively) [5].
Nonsense or frameshift mutations, which result in the
truncated gene product (and presumably non-functional
or dysfunctional BRCA protein), account for approxi-
mately 90% of the clinically important BRCA1/2 entries
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and approximately 50% fall within the large exon 11 (of
BRCA1 and BRCA2) alone [6]. Mutation-specific techni-
ques are rendered impractical because of the sheer
number of mutations (more than 850 clinically impor-
tant mutations can be found in BRCA1 and more than
750 can be found in BRCA2 [6]).
In addition to inherited breast and ovarian cancers, a
variety of inherited diseases, including familial adenoma-
tous polyposis (APC) [7], hereditary non-polyposis colon
cancer (MSH2/MLH1) [8], polycystic kidney disease
(PKD1) [9], neurofibromatosis (NF1 and NF2) [10,11],
and Duchenne muscular dystrophy (DMD) [12], are
caused by chain truncations as the primary mode.
Direct automated intra-exonic DNA sequencing is the
‘gold standard’ scanning method for detection of BRCA1/2
mutations (Myriad Genetics, Salt Lake City, UT, USA).
A variety of other approaches, including several electro-
phoretically based assays that essentially resolve the
mutant DNA or protein by mobility differences, are possi-
ble. These include the protein truncation test (PTT), con-
formation-sensitive gel electrophoresis (CSGE), and two-
dimensional gene scanning (TDGS) as well as variants of
these basic methods. Analogous to the electrophoretic
methods, denaturing high-performance liquid chromato-
graphy (DHPLC) is a highly sensitive method to detect
mutant-WT DNA heteroduplexes. High-throughput or
multiplexed mutation-specific methods (that is, requiring
a priori knowledge of possible mutations) such as DNA
microarrays and reverse transcription-polymerase chain
reaction (RT-PCR) are also possible. A recent review of
BRCA1/2 mutation detection methods [2] found that,
whereas the specificity was essentially 100% for most
methods, the sensitivity varied significantly: the sensitivity
of the different electrophoretic mobility-based DNA assays
ranged from 50% to 100%, that of the PTT was 75%, and
DHPLC was the top performer with a sensitivity of 100%
in all cases.
However, methods such as DNA sequencing, DNA
microarrays, and DHPLC are expensive to perform or
require expensive and specialized instrumentation or
both. Thus, despite its imperfect sensitivity, the PTT
assay is popular for its simplicity, cost-effectiveness, and
general accessibility to virtually any laboratory [5]. Con-
ventional PTT begins with PCR amplification of target
gene segments from the patient source material (for
example, genomic DNA or mRNA from blood). The
PCR primer pair incorporates additional sequences into
the amplicons required for subsequent protein produc-
tion, including an RNA polymerase promoter, a Kozak
(ribosome-binding) site, and start and stop codons. The
amplified DNA is then added to a cell-free transcrip-
tion-translation extract along with radioactive amino
acids (
35S-methione or
14C-leucine), and the expressed
protein is then analyzed by SDS-PAGE and autoradio-
graphy. Chain truncation mutations are detected by the
presence of a lower-molecular-weight (increased mobi-
lity) species relative to the wild-type (WT) protein band.
More recent variants of the SDS-PAGE-based PTT
include non-radioactive versions based on Western blot-
ting [13] or, as reported by us, using tRNA-mediated
protein engineering to fluorescently label the expressed
protein [14]. Additional benefits of the PTT include (a)
the potential to be one of the highest throughput muta-
tion scanning methods since 1 to 3 kb of DNA sequence
can be scanned from a single PCR, compared with 200
to 300 base pairs in many other methods [15,16], and
(b) the ability to detect large genomic deletions and
insertions as well as mRNA splicing errors that can be
missed by methods such as direct DNA sequencing and
DHPLC [16,17].
However, as with all of the electrophoresis-based
methods, PTT is inherently low-throughput and difficult
to automate, and results (which are based on visual
inspection of the gel) can be difficult to interpret,
thereby making them subject to human error [2].
Furthermore, mutations in the 5′ end of the BRCA gene
which result in small truncation fragments are missed
(not resolved on gel) [16] and this affects the diagnostic
sensitivity.
To overcome these limitations, we previously developed
[14] the first high-throughput solid-phase protein trunca-
tion test (HTS-PTT), which uses an industry-standard
microtiter-plate enzyme-linked immunosorbent assay
(ELISA) format, which can be implemented in any clinical
laboratory with minimal, inexpensive, and widely used
instrumentation. This assay, which we previously applied
to the detection of familial adenomatous polyposis [14],
used a triple-tag system comprised of N-terminal and
C-terminal epitope tags for normalization and mutation
detection, respectively, as well as directly incorporated bio-
tin labels as the capture tag for protein immobilization on
the ELISA plate. Unfortunately, biotin incorporation dur-
ing translation using tRNA-mediated protein engineering
occurs at very low efficiency, thereby adversely affecting
mutation detection capabilities and diagnostic sensitivity
(data not shown). Du and colleagues [18] later introduced
a two-tag variant of our assay as applied to the genetic dis-
order ataxia-telangiectasia; however, this variant lacks the
ability to normalize for the amount of total nascent pro-
tein that is expressed and captured on the ELISA plate,
critical for the reproducibility and accuracy required in a
clinical or diagnostic setting or both.
The next-generation HTS-PTT, reported here, uses
three different epitope tags - two in tandem at the
N-terminus (one detection and one capture tag) and
one at the C-terminus (detection tag) - added by using
specially designed PCR primers that amplify target gene
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cell-free expressed and simultaneously captured and
purified by epitope capture onto the ELISA plate, and
the remaining two tags enable N- and C-terminal detec-
tion (Figure 1). We have applied this improved assay for
the first time to the detection of truncation mutations
in exons 11 of the breast cancer susceptibility genes
BRCA1/2 and have evaluated it using 100 clinical geno-
mic DNA test samples.
Materials and methods
Human samples were obtained through the Women’s
College Research Institute (ref. no. 2007-0036-B) for
these experiments and for the collaboration with
AmberGen, Inc. (Watertown, MA, USA). All study sub-
jects provided informed written consent. For HTS-PTT
analysis, purified genomic DNA samples were provided
to AmberGen, Inc., in de-identified form, marked only
with non-descriptive alphanumeric codes along with
only the BRCA1/2 mutation status/designation, and no
identifying information or clinical annotation was pro-
vided to AmberGen, Inc.
DNA and polymerase chain reaction
One hundred human genomic clinical DNA samples
isolated from blood and previously characterized by
the conventional gel-based PTT (method as described
in [19]) were used for HTS-PTT. The genomic DNA
was extracted from peripheral blood leukocytes by
means of the Gentra Puregene Blood Kit (Gentra
Systems, Minneapolis, MN, USA). mRNA samples for
HTS-PTT were extracted from several BRCA mutant
cell lines (B-lymphocytes from blood) obtained from
the Coriell Cell Repository (Camden, NJ, USA); sam-
ples were extracted by means of the Qiagen Rneasy
Mini Kit (Qiagen, Germantown, MD, USA) and con-
verted to cDNA by means of the SMART™ PCR cDNA
Synthesis Kit (Clontech, Mountain View, CA, USA).
PCR amplification was carried out with 50 ng of geno-
mic DNA or cDNA, 0.245 μM each of the forward and
reverse primers, 2.5 mM MgCl2,0 . 2m Md N T P s
(each), and the Phusion Hot Start DNA Polymerase
with the HF Buffer (New England Biolabs, Ipswitch,
MA, USA). Amplification was performed as follows: an
initial denaturation at 95°C for 2.5 minutes, 40 cycles
of denaturation at 95°C for 30 seconds, annealing at
67.5°C for 45 seconds, extension at 72°C for 3.5 min-
utes, and a final extension st e pa t7 2 ° Cf o r1 0m i n u t e s .
The gene-specific PCR primers used on genomic DNA
or cDNA templates were as follows:
Forward primer: 5′-ggATCCTAATACgACTCACTA-
TAgggAgACCACCATgTACACCgACATCgAgATgA
ACCgCCTgggCAAgggAggACAgCCTgAACTCgCTC-
CAgAggATCCggAAgAT[gene-specific hybridization
region]-3′.
Forward primer key: The italicized nucleotides corre-
spond to the T7 promoter, the underlined ATg is the
initiation codon, the boldface nucleotide region codes for
the N-terminal detection tag (VSV-G; YTDIEMNRLGK),
the underlined boldface nucleotide region codes for the
Figure 1 Schematic representation of the high-throughput solid-phase protein truncation test (HTS-PTT). The next-generation HTS-PTT
uses three different epitope tags - two in tandem at the N-terminus (one capture and one detection tag) and one at the C-terminus (detection
tag) - added using specially designed primers (not shown here). The chain truncation mutations are calculated using % C/N (the C- to N-
terminal signal ratio of a given sample normalized against known wild-type controls).
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bracketed nucleotide sequence codes for the BRCA-
specific complementary region (see below), and the
remaining nucleotide sequences correspond to the Kozak
(ribosome binding) and spacer regions.
Reverse primer: 5′-TTATTACAgCAgCTTgTg-
CAggTCgCTgAAggT [gene-specific hybridization
region]-3′.
Reverse primer key: The boldface nucleotides code
for the C-terminal detection tag (p53-derived tag;
TFSDLHKLL), the underlined TTATTA is two succes-
sive stop codons, and the bracketed nucleotide sequence
codes for the BRCA-specific complementary region (see
below).
Gene-specific hybridization regions and sequence of
the primers are provided in Table 1. After amplification,
the quality and quantity of the PCR products were ana-
lyzed by agarose gel electrophoresis. Refer to Figure 2
for an example of agarose gel analysis of the five differ-
ent PCR segments, and refer to Figure 3 for the names
of the aforementioned cell lines used for the mRNA
samples.
Cell-free protein synthesis
The rabbit reticulocyte cell-free reaction mixture con-
tained 8.5 μL of TNT T7 Quick Rabbit Reticulocyte
Lysate for PCR DNA (Promega, Madison, WI, USA),
0.5 μL of a complete amino acid mix (50 μMf i n a lf o r
each), and 1 μL of PCR-amplified DNA (approxi-
mately 100 to 200 ng). The coupled transcription-
translation reaction was allowed to proceed for
45 minutes at 30°C.
HTS-PTT
MicroLite 2 + 96-well microtiter plates (Thermo Fisher
Scientific, Waltham, MA, USA) were pre-coated with
0.5 ng/μL of an anti-HSV tag monoclonal antibody
(EMD Biosciences, La Jolla, CA, USA) solution in
50 mM sodium carbonate at a pH of 9.5. The plates
were then washed four times with Tris-buffered saline
(TBS) containing 0.05% (vol/vol) Tween-20 (TBS-T) and
blocked for 30 minutes with TBS-T containing 1%
(wt/vol) bovine serum albumin (BSA). After protein
synthesis, the reaction mixture was diluted 100-fold
Table 1 BRCA1/2 exon 11 primers and segments for high-throughput solid-phase protein truncation test
Segment Nucleotides Segment size, base pairs Primer sequence (5’ to 3’) F, forward; R, reverse; subscript ‘I’, intronic primer
BRCA1
a
1 123,126-125,033 1,908 F: gCTTgTgAATTTTCTgAgACggAT
R: TgTATTCTgCAAATACTgAgCATCAAg
2 124,617-126,578 1,962 F: gTCAATCCTAgCCTTCCAAgAgAA
RI: gggCAAACACAAAAACCTggTTCC
BRCA2
a
1 25,758-27,458 1,701 FI: TTTTgTCACTTTgTgTTTTTATgTTTAgg
R: gCCAgCAAACTTCCgTTTAATTTC
2 27,174-29,330 2,157 F: AACCATAATTTAACACCTAgCCAAAAg
R: TgAAgAgCTAgTCACAAgTTCCTC
3 29,181-30,743 1,563 F: gATTCTggTATTgAgCCAgTATTgAAg
RI: CACgAAAggTAAAAATgAACACTTACC
aNational Center for Biotechnology Information (NCBI) reference sequences: Ng_005905.2 for BRCA1 and Ng_012772.1 for BRCA2, both numbered from whole
sequence entry. BRCA1/BRCA2, breast and ovarian cancer susceptibility gene 1/2.
Figure 2 Example of agarose gel analysis of five different
polymerase chain reaction (PCR) segments spanning exons 11
of BRCA1 and BRCA2. The segment sizes correspond to the values
in Table 1, demonstrating the quality and quantity of the PCR
fragments. BRCA1/BRCA2, breast and ovarian cancer susceptibility
gene 1/2.
Lim et al. Breast Cancer Research 2010, 12:R78
http://breast-cancer-research.com/content/12/5/R78
Page 4 of 9with TBS-T further supplemented with 0.1% Triton
X-100, 1% (wt/vol) BSA, and one of either the N- or
C-terminal detection antibodies (anti-VSV-G-HRP at
40 ng/mL, Clone P5D4, Roche Applied Science, Indiana-
p o l i s ,I N ,U S A ;o ra n t i - p 5 3 - H R Pa t8 0n g / m L ,C l o n e
BP53-12, Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA; HRP = horseradish peroxidase). Alternatively,
both the anti-VSV-G-HRP antibody and an anti-p53-AP
antibody (Santa Cruz Biotechnology, Inc.; AP = alkaline
phosphatase) could be used in the same solution (same
concentrations as above) to ultimately allow both signals
to be detected in the same well using this dual-reporter
system [14]. In either case, 100 μL of the diluted reac-
tion mixture was then added to each well of the afore-
mentioned antibody-coated microtiter plates and
incubated for 45 minutes on an orbital shaker. The
plate was washed four times with TBS-T and developed
using a chemiluminescent HRP substrate (Super Signal
Femto; Pierce Chemicals, Rockford, IL, USA). If the
dual-reporter system was used, a chemiluminescent AP
substrate was added first (Roche Applied Science), and
after signal readout, the plates were washed four times
with TBS-T and developed using the HRP substrate
described above. All signals were read using a Lumi-
Count luminescent plate reader (Packard Biosciences,
Meriden, CT, USA). The background levels correspond
to cell-free protein synthesis reactions that lacked only
the added DNA in the reaction mixture.
Results and Discussion
The basic HTS-PTT
A schematic of the HTS-PTT assay is shown in Figure 1
(PCR and expression not shown). BRCA1/2 open read-
ing frames are amplified and divided into ‘working’
Figure 3 Clinical validation of high-throughput solid-phase protein truncation test (HTS-PTT) on BRCA1/2 exons 11 for inherited breast
cancer susceptibility. One hundred blood-derived clinical genomic DNA samples were analyzed by HTS-PTT. (a) BRCA1 covered in two
overlapping segments. (b) BRCA2 covered in three overlapping segments. (c) Standard curve of different protein inputs into the HTS-PTT
enzyme-linked immunosorbent assay (ELISA) using serial dilutions of known wild-type samples. % C/N is the C- to N-terminal signal ratio of a
given sample normalized against known wild-type controls. The green bars and lines indicate the designated threshold (3 standard deviations
below the mean for the wild-type cohort), above which samples are scored as wild-type (blue bars) and below which samples are scored as
mutant (red bars). Yellow bars indicate the predicted mutant % C/N based on the known wild-type standard curves (c). Black bars denote false-
positives. The tick mark on the x-axis divides the 50 patients with known BRCA1/2 truncation mutations (left of tick mark) from the 50 wild-type
patients (right of tick mark). BRCA1/BRCA2, breast and ovarian cancer susceptibility gene 1/2; RLU, relative light unit.
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75-kDa overlapping protein segments within exons 11 of
BRCA1 and BRCA2; Table 1). As detailed in the Materi-
als and methods section, the PCR also incorporates all
of the needed expression sequences (for example, pro-
moter) and epitope tag sequences, as required by the
HTS-PTT method. After cell-free coupled transcription/
translation of the PCR products, the nascent proteins
are analyzed by HTS-PTT for truncation mutations.
The N-terminal capture tag (HSV epitope) is used for
concurrent immobilization/purification of the cell-free
expressed protein onto antibody-coated microtiter-
well ELISA plates. The N- and C-terminal detection
tags (VSV-G and p53 epitopes, respectively) are sub-
sequently used for measuring the relative level of shor-
tened protein produced by the chain truncation
mutation (Figure 1). Detection is achieved using HRP-
labeled epitope tag antibodies and a highly sensitive che-
miluminescent readout in separate replicate wells of the
ELISA plate. Alternatively, if tighter control is desired, a
per-well normalization is possible, in which N- and C-
terminal epitope tag antibodies (each carrying a different
enyzyme reporter) are used in the same wells [14].
Polymerase chain reaction optimizations on BRCA1/2 for
HTS-PTT
Although lengthy sequences need to be added by the
PCR primers in the HTS-PTT process, we have fully
optimized the PCR conditions so that this can be
achieved in a single reaction (one-step PCR) with a sin-
gle primer pair (approximately 130-mer forward and
approximately 60-mer reverse) as opposed two sequen-
tial PCRs commonly used to add sequences of this
length to an amplicon. This is important since two
sequential PCRs are not compatible with standard clini-
cal PCR clean-room practices (that is, separate pre- and
post-PCR rooms). A significant problem we encountered
is that the lengthy one-step PCR primers are prone to
form non-specific or primer dimer extension products
(or both) that produce substantial background in
the HTS-PTT since both can be expressed as protein
and can contain the in-frame epitope tags. Optimizing
factors such as primer concentration, annealing tem-
perature, magnesium concentration, and the use of a
heat-activated ‘hot start’ DNA polymerase were found to
be critical in avoiding this problem (data not shown).
Extreme care should be taken to avoid the primer dimer
extension products in the one-step and even the two-
step PCR methodologies as these products are ideal
expression templates and can interfere with HTS-PTT
even when present at levels near or below the detection
limit of conventional ethidium bromide agarose gel elec-
trophoresis. For instance, the quantity and quality of the
genomic DNA input into the PCR should be closely
monitored (discussed later) as, in general, less cognate
template means that more primer dimer extension pro-
ducts will be formed. All experiments described in this
article use this optimized one-step PCR method (see
F i g u r e2f o ra ne x a m p l eo fa g a r o s eg e la n a l y s i so ff i v e
different PCR segments).
Linearity of the HTS-PTT assay
After the HTS-PTT assay (Figure 1), the C-terminal sig-
nal arising from full-length protein in a given sample is
normalized against its N-terminal signal representing
total nascent protein produced and is captured on the
ELISA plate. These C-terminal-to-N-terminal signal
ratios (C/N ratios) of the test samples are calculated as
a percentage of the ratio arising from known BRCA WT
control samples (% C/N). Thus, in theory, BRCA WT
samples would have a 100% C/N ratio and heterozygous
BRCA mutants would have a 50% ratio.
In practice, however, the % C/N ratios of the BRCA
heterozygous mutants deviate from 50% in either direc-
tion (for example, Figure 3a and 3b; red bars for various
segments), a phenomenon that can be explained by sev-
eral possible factors. All of these factors essentially
derive from the coexistence of two protein species in
the heterozygous mutant samples (full-length and trun-
cated) as opposed to a single protein species in the WT
samples (full-length). One likely factor is skewed ratios
of the actual mutant and WT proteins within a hetero-
zygous sample, either in the expressed sample itself or
ultimately what is captured on the ELISA plate, and this
could occur through various mechanisms. For example,
the enhanced expression or plate-binding kinetics of the
mutant protein, owing to its decreased size compared
with the WT [14], could increase the ratio of mutant
protein actually bound to the ELISA plate to greater
than 50% and therefore skew the % C/N ratio to less
than 50%. Similarly, nucleotide composition differences
between the mutant and WT can ultimately alter the
mRNA secondary structure and hence result in differ-
ences in expression efficiency between the mutant and
W T ,a n dt h i sm a yb ep a r t i c u l a r l ya p p l i c a b l et ol a r g e r
deletions or insertions and could skew the % C/N in
either direction. Differences in the physical accessibility
(that is, steric hindrance) of the N-terminal epitope tag
between the mutant and WT proteins could be caused
by different secondary and tertiary folding structures
between the two protein species and thereby could skew
the ratio of mutant and WT protein captured on the
ELISA plate.
Importantly, these effects could vary among the differ-
ent BRCA test segments as well as from sample to sam-
ple (depending on the position of the mutation). As
seen in Figure 3a and 3b (red bars; mutant samples), the
former is the overriding factor as each BRCA segment
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example, BRCA2 exon 11 segment 1 mutants fall in the
range of 30% ± 6% C/N, whereas BRCA2 exon 11 seg-
ment 2 mutants fall in the range of 61% ± 5% C/N (Fig-
ure 3b). However, intra-segment variation in the % C/N
ratio for the mutants is also apparent.
Figure 3c shows an example of linearity of the HTS-
PTT assay as a function of different amounts of trans-
lated protein input into the ELISA assay. The standard
curves in Figure 3c are for the N- and C-terminal detec-
tion tags of the WT reference sample for BRCA2 exon
11 segment 1 (n = 7). Importantly, although this verified
excellent linearity of the assay over an approximate
10-fold range (R
2 = 0.99), the y-intercepts of these N-
and C-terminal signal curves do not pass precisely
though zero. A critical consequence of this is that, in
order to correctly compare the % C/N ratio of the WT
reference sample with that of the test samples, the input
amount of translated protein (for the ELISA) must be
standardized among all of the samples. This is easily
and typically achieved by normalizing the input amount
of PCR product into the cell-free protein expression
reaction and can be quality-controlled by monitoring
the raw N-terminal signals (total expressed and captured
protein).
Clinical validation of a genomic DNA-based HTS-PTT on
BRCA1/2 using a 100-member training sample set
To evaluate the HTS-PTT for BRCA mutation analy-
sis on clinical samples, we designed primer pairs to
fully cover the large exons 11 of both BRCA1 and
BRCA2, dividing them into two and three overlapping
segments, respectively; each segment was roughly 2
kb in size. One hundred clinical genomic DNA sam-
ples collected from blood were analyzed by means of
HTS-PTT (25 BRCA1 mutants, 25 BRCA2 mutants,
and 50 normal controls). The mutation status of the
samples had been previously determined by conven-
tional gel-based PTT. HTS-PTT results are shown in
Figure 3a and 3b. The range of mutations covered is
detailed in Supplemental table S1 in Additional file 1.
This sample cohort contained deletions as large as 40
bases, all of which were detected by our HTS-PTT
method.
Despite the aforementioned segment-specific % C/N
ratios for heterozygous mutants in HTS-PTT, a fixed
method based on the variability within the WT cohort was
still able to be employed for setting the diagnostic scoring
cutoffs. HTS-PTT scoring cutoffs for a positive protein
truncation were fixed at 3 standard deviations below the
mean of the 50 normal (WT) samples (on a segment-by-
segment basis) for an approximately 99% confidence inter-
v a l .W i t ht h e s ec u t o f f s( F i g u r e3 aa n d3 b ;g r e e nb a ra n d
green line), the sensitivity and specificity of the HTS-PTT
(as compared with conventional PTT) were 100% and
96%, respectively. Note that the % C/N ratios for the only
two false-positive calls (Figure 3a and 3b; black bars) were
just slightly below the cutoff and were likely due to assay
variance (approximately 1/100 false-positive calls are sta-
tistically expected with the aforementioned 99% confi-
dence interval used). Finally, it is worth noting that, in the
HTS-PTT assay, raw signal-to-noise ratios of the N- and
C-terminal detection were never less than 20:1 and in
most cases were greater than 100:1.
An mRNA-based HTS-PTT for BRCA1/2
To obtain full BRCA1/2 (open reading frame) coverage
using a genomic DNA test, roughly 50 HTS-PTT seg-
ments per patient would be required because of the large
number of small exons in both genes, outside of the large
exons 11. The high-throughput ELISA-based HTS-PTT is
certainly more amenable to such large segment numbers
than the conventional gel-based PTT. However, one way
to further alleviate this issue is to design an mRNA-based
assay, which would allow the BRCA1/2 transcripts to be
divided evenly into approximately 10 HTS-PTT segments
of roughly 1 to 2 kb in size (an effective size for the HTS-
PTT). To demonstrate the feasibility of this approach, we
performed experiments on cDNA created from cell lines
(obtained from the Coriell Cell Repository) having known
BRCA1/2 truncating mutations (Coriell Institute for Medi-
cal Research, Camden, NJ, USA). Figure 4 shows BRCA1
results for one gene segment on 13 cell lines (1 mutant)
and again demonstrates 100% accuracy. Importantly, non-
sense-mediated decay of the mutant transcripts was not
found to be a problem in this small set, but should the
problem occur, mutation detection sensitivity as low as
25% is possible with HTS-PTT [14].
Conclusions
The HTS-PTT has the potential to cover the vast major-
ity of clinically important BRCA1/2 mutations (approxi-
mately 90% of BIC entries) using a rapid and facile
microtiter-plate ELISA assay. The assay avoids radioac-
tivity as well as very low-throughput SDS-PAGE ana-
lyses and, unlike SDS-PAGE-based PTT, uses concrete
mathematical thresholds to distinguish mutant and WT
samples. Here, in BRCA1/2 exons 11, clear thresholds
could be established to provide 100% diagnostic sensitiv-
ity and 96% specificity for truncating mutations in these
100 clinical genomic DNA samples. Furthermore, an
mRNA-based HTS-PTT shows the feasibility of covering
all of BRCA1/2 and would require about 10 segments.
Overall, the assay affords a simple, low-cost, and high-
throughput method of BRCA analysis that would be
readily accessible to virtually any laboratory with rudi-
mentary instrumentation (PCR machine and basic
ELISA plate reader).
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Additional file 1: Supplemental table S1 - BRCA1/2 Mutations
Covered by the HTS-PTT. This table lists the mutation designations for
the 50 patient genomic DNA samples tested which were positive for
BRCA1/2 truncation mutations. HTS-PTT segments containing the
mutation and the measured % C/N ratios are also listed.
Abbreviations
BIC: Breast Cancer Information Core; BRCA1/BRCA2: breast and ovarian cancer
susceptibility gene 1/2; BSA: bovine serum albumin; C/N: C-terminal to N-
terminal signal (ratio); DHPLC: denaturing high-performance liquid
chromatography; ELISA: enzyme-linked immunosorbent assay; HRP:
horseradish peroxidase; HTS-PTT: high-throughput solid-phase protein
truncation test; PCR: polymerase chain reaction; PTT: protein truncation test;
TBS: Tris-buffered saline; TBS-T: Tris-buffered saline containing 0.05% (vol/vol)
Tween-20; WT: wild-type.
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